From: Controversies in intraocular lens implantation in pediatric uveitis
Sources | No. of patients | Etiology | Age at presentation of Ds in years (median) | Age at Cataract surgery (years) | PCIOL (in the bag) (n =eyes) | Aphakia (n=eyes) | Complications (n=eyes) | Immunosuppression | Follow-up | Comments | Visual outcome pseudophakia (n=eyes) | Visual outcome aphakia (n=eyes) |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Probst and Holland [17] (1996) | 7 (8 eyes) | JIA | Â | Adults (5) <10 (2) | PMMA | Â | Glaucoma (4), PCO (5) | Steroids | 16.6Â months | Â | All >20/40 | Â |
Lundvall and Zetterstrom [28] (2000) | 7 (10 eyes) | JIA |  | 3.5–10 6.5 (mean) | HSM-PMMA 10 |  | Glaucoma (7), PCO (5), 2nd Sx for membranes (8) | Steroids, methotrexate | 28 months | Uveitis controlled | 20/20–20/50(8) <20/50(2) |  |
BenEzra and Cohen [15] (2000) | 17 (20 eyes) | JIA (8) |  | 4–17 | 10 PMMA (7), diffractive (3) | 7 | Glaucoma (4), PS (3), CME (3) | Steroids | 60 months | In U/L, CL poorly tolerated, JIA results guarded, uveitis active | JRA 6/9–6/6(1) 6/60(1) 6/240(3) | JRA 6/9–6/6(1) 6/240(3) |
Lam et al.[21] (2003) | 5 (6 eyes) | JIA (5) | 8.5 | 7–12 8.5 (median) | 6 PMMA (4), HSM-PMMA (1), acrylic hydrophobic (1) |  | PCO (6), glaucoma (2), CME (1) | Methotrexate | 43.5 months | Uveitis controlled | ALL >20/40 |  |
Nemet et al. [16] (2007) | 18 (19 eyes) | JIA (10), non-JIA (9) | JIA (0.9–14) Non-JIA (4.6–17) | JIA (11.8+/−4.6), non-JIA (17.1+/−4.5) | PMMA (7), acrylic hydrophobic (11), acrylic hydrophilic (1) |  | PCO (10), glaucoma (4), CME (1), 2nd Sx (11) | Steroids, methotrexate, cyclosporine | 45 months | No difference in visual outcome in both groups | >20/40 (13) <20/40 (6) |  |
Quinones et al. [8] (2009) | 34 (48 eyes) | JIA (27), non-JIA (13) | 6.7 (4–16) | 9.8 (4–17) | 13 PMMA | 28 | Glaucoma (3), PCO (4), RD (3), CME (4), membranes (2) | Steroids, methotrexate | 0.3–15.7 years (4.1 years) | Uveitis controlled, postsegment involved (17) | 92 % improved >20/40 (8) 20/50–20/70(4) 20/80–20/200(0) <20/400(1) | >20/40 (9) 20/50–20/70(6) 20/80–20/200(5) <20/400(8) |
Sijssens [41] (2010) | 29 (48 eyes) | JIA | 4.4 | 6.3 aphakia, 7.6 pseudophakia | 29 acrylic 24, PMMA 5 | 19 | Ocular HTN, glaucoma, CME, optic disc involvement | Methotrexate | 7 years | Uveitis controlled, aphakic surgeries till 2002, complications same in both groups | >20/40 (25) 20/40–20/200(3) <20/200(1) | >20/40 (13) 20/40–20/200(4) <20/200(2) |
Terrada et al. [6] (2011) | 16 (22 eyes) | JIA (9), non-JIA (7) | 5Â years | 9.5 (median) | 22 HSM-PMMA | Â | PCO (2), glaucoma (4), CME (3) | Methotrexate, azathioprine | 6.2Â years | Uveitis controlled | 0.3 or better, log MAR | Â |